

## Enduring Learner Notification

Society of Gynecologic Oncology  
2024 SGO Targeted Therapy Advanced Bootcamp  
October 7, 2024 – April 7, 2025  
Online

### Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163.

Professions in scope for this activity are listed below.

### Physicians

Amedco LLC designates this **enduring material** for a maximum of **2.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Nurses

Amedco LLC designates this activity for a maximum of **2.75 ANCC** contact hours.

### Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of **2.75** knowledge-based CPE contact hours.

**UAN:** JA4008163-9999-24-168-H01-P | JA4008163-9999-24-168-H01-T

***NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.***

### Objectives - After Attending This Program You Should Be Able To

1. Understand when to order molecular and genetic testing for patients with gynecologic cancers.
2. Analyze molecular results to review available therapeutic options for women with gynecologic cancers.
3. When given a patient scenario, recommend the best therapy option for a patient and provide patient education for this therapy.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Terri	Earles	NA
Kathleen	Lutz	AstraZeneca:Scientific/Medical Advisory Board Member,Merck:Scientific/Medical Advisory Board Member
Jennifer	MacDonald	Glasko Smith Kline:Speakers Bureau,Mersana:Scientific/Medical Advisory Board Member
Jessica	Martineau	NA
Tracy	Sandstrom	NA
Stephanie	Shuey	ImmunoGen:Scientific/Medical Advisory Board Member,GSK:Other